The invention pertains to
utilization of pterostilbene for augmenting immunogenicity of
cancer cells treated with various therapies.
OCEANSIDE, CA--(iHub October 16, 2017) - Therapeutics Solutions
International, Inc., (OTC Markets:
TSOI) announced the filing of an additional patent on the use
of pterostilbene.
TSOI had previously announced the granting of U.S. Patent No.:
9,682,047 for our flagship product ProJuvenol® as an
immuno-adjuvant to FDA approved chemotherapies and immunotherapies.
In addition we have also filed an application with the U.S. Patent
and Trademark Office for the means of augmenting circulating
endogenous stem cells through administration of an effective amount
of pterostilbene or derivatives thereof.
"Today's announcement of the filing of our third pterostilbene
patent represents several years of research and literature review
and was developed to utilize the ability of the immune system to
augment the possibility of increasing overall survival of glioma
patients after treatment with conventional therapies. Our data
suggests that when pterostilbene is combined with brain cancer
therapeutics such as Gefitinib, Sertraline, or Temozolomide, the
prognosis is vastly improved", said co-inventor Timothy Dixon,
President and CEO.
"What is particularly interesting is that pterostilbene appears
to make cancer cells more visible to the immune system subsequent
to their being attacked by conventional drug approaches", said Dr.
Thomas Ichim, Board Member of TSOI and co-inventor of patent.
"Specifically, we observed that this increase of immunogenicity
that pterostilbene causes in chemotherapy treated cancer cells
allows for enhanced immunity to cancer cells that have escaped
chemotherapy, thus theoretically enhancing patient prognosis."
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases. Immune modulation
refers to the ability to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is www.therapeuticsolutionsint.com.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION